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Abstract 
 
Context  
Randomised controlled trials (RCTs) can answer questions of efficacy, but rarely generate a 
complete safety profile. Long term pharmacovigilance studies complement RCTs.  
 
Objectives 
Level I evidence supports short term efficacy of opioids in reducing refractory dyspnoea. This 
study aims to determine: the minimum effective daily dose of sustained release morphine to reduce 
refractory breathlessness; and whether net clinical benefits are sustained safely. 
 
Methods 
In a phase II dose increment study, 10mg sustained release morphine was administered daily, and 
increased by 10mg daily each week to a maximum of 30mg daily. The participant was withdrawn 
if there were unacceptable side-effects or no response to maximum dose. If participants had a 10% 
improvement in dyspnoea over their own baseline, they joined a long-term phase IV 
effectiveness/safety study at that dose. Complying with STROBE guidelines for reporting 
observational studies, response and side-effects are described, with demographic and clinical 
characteristics of responders. 
 
Results 
Eighty five participants (65 males, mean age 74, 59% with chronic obstructive pulmonary disease 
(COPD) provided >30 patient-years of data. Fifty three participants derived ≥10% benefit (35.4% 
improvement over baseline) giving a response rate of 62% (number needed to treat of 1.6); for 
70%, this dose was 10mg/24hours. Benefit was maintained at three months for 28 (33%) people. 
Breathlessness was reduced significantly (p<0.001) but constipation increased (p<0.001) despite 
aperients. There were no severe adverse events including no respiratory depression nor 
hospitalisations.  
 
Conclusion 
Ten mg of sustained release oral morphine daily is safe in this population, and effective for most 
people.   
 
Key words: Palliative care, Dyspnea, Opioids, Clinical effectiveness, Respiratory 
 
Running Title : Opioid dose ranging and effectiveness 
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Introduction  
Randomised controlled trials can answer questions of efficacy, and although toxicities are reported, 
these studies are usually of the briefest duration in order to see a clinical benefit and rarely 
designed with power to detect significantly different levels of rare toxicities. The optimal way to 
answer questions of safety, sustained benefits and long term toxicities is through ongoing 
pharmacovigilance studies in order to understand the net clinical benefit in everyday practice. 
Pharmacovigilance studies are, by definition, uncontrolled studies. 
 
Dyspnoea is more than a sentinel clinical sign; dyspnoea, experienced acutely or chronically, 
threatens a person’s very existence, psychological well-being and social functioning. Once 
reversible causes of dyspnoea have been addressed, residual symptomatology is ‘refractory 
dyspnoea’.[1] 
 
At a population level, refractory dyspnoea is a significant chronic burden for a sizeable number of 
individuals.[2,3] Moreover, with many respiratory, cardiac, haematological, oncological and 
neuromuscular disorders, breathlessness is likely to worsen over time.[4] There are no symptom-
specific medications to treat refractory dyspnoea registered with the major pharmaceutical 
regulatory bodies such as the Food and Drug Administration (FDA; USA), European Medicines 
Evaluation Agency (EMEA; Europe) or Therapeutic Goods Administration (TGA; Australia). 
 
Evidence, including an adequately powered randomised study and a meta-analysis, demonstrates 
that opioids reduce the intensity of refractory breathlessness.[1,5] The effect of opioids on the 
subjective sensation of breathlessness is further supported by recent evidence demonstrating that 
blockade of endogenous opioids during exercise worsens the perception of breathlessness without 
changing the ability to exercise in people with chronic obstructive pulmonary disease (COPD).[6] 
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 While data supporting opioids for the treatment of refractory dyspnoea are clear, studies to date 
have not yet defined the minimum effective dose;[1,7,8] furthermore since the study by Abernethy 
et al which evaluated the efficacy of 20mg oral morphine daily, a 10mg per 24 hour preparation 
has become available.  
 
Propsective data about long term safety is lacking.  Many clinicians continue to extrapolate from 
the acute toxicity witnessed when frail or infirm opioid naïve patients were administered opioids in 
the emergency room or post-operatively, with severe side effects including confusion, drowsiness 
and respiratory depression.[9,10] These observations, first made more than six decades ago, still 
largely underpin the poor uptake of an entirely different way of prescribing opioids for refractory 
breathlessness - regular low doses. International guidelines for opioids in refractory breathlessness 
continue to reflect concerns generated by the way opioids are used for acute pain.[11,12]  Lack of 
dosing and safety data continue to be a major barrier in the registration of a dyspnoea-related 
indication for morphine.  
 
Given the chronic nature of breathlessness for many people, there are justifiable concerns that 
benefits of opioids may diminish over time. There have been no longitudinal, prospective data 
describing the net clinical benefits of low-dose opioids in people with chronic refractory dyspnoea. 
 
The aims of the phase II exploratory open-label, dose-ranging study were to define the minimum 
dose of morphine for reducing chronic refractory dyspnoea by  ≥10%; a phase IV follow-on study 
sought to define the safety of daily sustained release morphine and longer-term clinical 
effectiveness. The best level of evidence for phase IV outcomes is generated by prospective cohort 
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data collection. Results complement current phase III evidence about the short-term efficacy of 
opioids in relieving breathlessness. 
 
Methods 
Study Design 
This study comprised phase II and IV components (Figure 1). Phase II was an open label, 
prospective study of once-daily sustained-release opioid (morphine sulphate 10mg / 24 hours 
titrated weekly by 10mg / 24 hours in non-responders up to a maximum of 30mg / 24 hours) 
administered with aperients (sodium docusate with sennosides). If at any weekly review the 
participant had a reduction of ≥10% over baseline in dyspnoea intensity without side-effects, they 
entered the long-term safety and effectiveness phase IV study. Any unresolved significant side-
effects at any time or a lack of response by the end of the three week titration during the phase II 
component of the study resulted in participant withdrawal from the study. 
 
Study Participants 
Participants were opioid-naïve outpatients aged ≥18 years with breathlessness scored at >2 on the 
modified Medical Research Council (MRC) scale [13] (Table 1). Any underlying reversible causes 
of the dyspnoea must have been maximally treated, as assessed by a consultant physician whose 
area of practice was most relevant to the cause of this person’s dyspnoea (e.g. a cardiologist for 
someone with cardiomyopathy). Participants must also have been on stable medications and 
oxygen (if required) for the seven days before commencing the study and an estimated prognosis of 
>1 month. 
 
Exclusion criteria included: regular use of any opioid medication in the two weeks before 
screening; a true hypersensitivity reaction to opioids; a history of substance misuse; use of 
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monoamine oxidase inhibitors in the last two weeks; functional status <50 on the Australian-
modified Karnofsky Performance scale (AKPS) [14] (Table 2); a calculated creatinine clearance of 
less than 15ml/min (as calculated using the MDRD formula [15]); pregnancy; confusion (less than 
24/30 on a Mini-Mental State Examination(MMSE) [16]); or unwilling or unable to complete the 
study measures. 
 
Settings 
Participants were recruited from four tertiary university teaching hospitals in two states of 
Australia between July 2007 and October 2009. Data collection was completed in January 2010. 
Lead study investigators were respiratory and palliative medicine physicians although referrals 
were encouraged from all disciplines including cardiology and oncology.  
 
Study Withdrawal 
Withdrawal from the study could be initiated at any time by the participant. Other reasons for 
withdrawal included AKPS [14] falling below 30, a sudden increase in dyspnoea, or participant 
death.  
 
Measurements 
Intensity of dyspnoea was the primary outcome, measured as subjective breathlessness on a 
100mm visual analogue scale (VAS) ‘right now’ anchored at 0mm as “no breathlessness” and at 
100mm as “worst imaginable breathlessness”. Participants recorded dyspnoea twice daily in a 
purpose-printed diary. 
 
During the phase II dose-ranging sub-study, morning and evening dyspnoea VAS scores recorded 
on days 5-7 of each 7 day week (i.e., during steady state) were averaged and contributed to 
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assessments of the number of people who responded to morphine and the dose at which they 
responded; an individual improvement of 10% over baseline was considered, a priori, as a 
clinically significant improvement, consistent with previous studies of similar interventions.[1,5] 
 
During the phase IV long-term effectiveness component of the study, the number of people still on 
opioids at three months, the dose of opioid at three months, and the number of dose changes since 
entry to this sub-study were recorded. Side-effects at any time causing cessation of the medication 
were a key secondary outcome.  
 
Data collection and data quality 
Data were collected, coordinated centrally by the lead site and entered contemporaneously on a 
customised 128-bit secure web-based research data management system (www.caresearch.com.au) 
so any discrepancies could be addressed immediately. 
 
Sample size 
Given the overall health of the target population, it was expected that, on average, individuals 
would participate for 3 months. This study was pragmatically built around a goal of collecting 25 
patient-years of data in the phase IV arm.  During study planning, it was anticipated that this would 
require 100 participants to achieve this. 
 
Analysis 
Basic descriptive statistics were used to define the population and their response to opioids. 
Intensity of breathlessness was described at baseline, at completion or withdrawal from the phase 
II dose ranging period, and at three months or the last recorded level in the long-term phase IV 
effectiveness period. Comparisons were made of key demographic and clinical factors for people 
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who did and did not progress to the phase IV study using Chi-square tests. Significance was 
assumed at p<0.05.  A comparison of the number of people who rated breathlessness or 
constipation as one of their problems at the beginning and end of the study were compared using 
McNemar’s test with continuity correction. To confirm the direction and magnitude of primary 
outcome, data were re-analysed using 15% and 20% improvements in dyspnoea at the end of phase 
II.  
 
Ethics, consent and trial registration 
The research was approved by all participating institutions’ Research and Ethics Committees. All 
participants provided written informed consent before participating in the study. The study 
received Clinical Trials Notification approval to use KapanolTM for an unregistered indication. The 
trial was registered with the Australian and New Zealand Clinical Trials Registry 
(ACTRNO12606000269538). 
 
Reporting 
This paper complies with the STROBE reporting requirements for observational studies.[17] 
 
Results  
Participant Flow and Study Population 
A total of 202 people with dyspnoea were screened and 85 participated in the study (Figure 2). 
Participant characteristics are summarised in Table 2. 
 
Phase II Dose Ranging  
At the end of the phase II period, the average VAS score for intensity of dyspnoea had fallen from 
a baseline of 51.9mm (Standard deviation (SD) 19.2; median 56.8; range 11.0-81.3) to 40.2 (SD 
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20.1; median 39.8; range 1.8 – 86.5) for all 85 participants the mean sustained release morphine 
dose was 16.6mg (SD 8.1; median 10.0). Thirty two participants either derived no benefit at the 
maximum dose of 30mg of sustained release morphine (n=9), lacked benefit at other doses (n=3), 
had unacceptable side-effects (n=15), or withdrew for reasons other than the therapy (death n=4, 
clinical request n=1). (Figure 2) For the 15 with side-effects, these included; drowsiness (n=4); 
confusion (n=3); and constipation (n=2; Figure 2) all of which reversed rapidly with cessation of 
medication. No one required hospitalisation for any toxicity. 
 
On an intention-to-treat basis, the response rate at the end of the phase II period was 53/85 (62%), 
giving a number needed to treat of 1.6, and a number needed to harm of 4.5. If, in the phase II 
period of the study, the clinical response threshold indicating successful therapeutic response was 
increased to 15% or 20% improvement over baseline dyspnoea scores, then 43 individuals (54%) 
and 35 individuals  (44%) respectively, would have met these revised response criteria. 
 
Phase IV Long-term Effectiveness  
A total of 53 participants derived at least a 10% improvement over their own baseline 
breathlessness without unacceptable side-effects and proceeded to the long-term phase IV 
effectiveness period, on an average dose of 14.0mg (SD 6.3) of sustained release morphine 
sulphate per 24 hours. (Table 3) 
Of the responders, 70% had benefit at 10mg of sustained release morphine in 24 hours, 23% at 
20mg, and 8% at 30mg. For people entering the phase IV period, the average improvement in 
scores from their own baselines as they entered phase IV was 17.5mm (SD 11.7). (Table 3) A total 
of 29.5 years of data were collected in the phase IV period (mean 205.6 patient days per participant 
entering the phase IV period) within a total of 32.5 patient years of data overall.  
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Withdrawal from the phase IV study included 15 people who withdrew because of side effects 
(constipation (n=6); drowsiness (n=4); nausea (n=3); and vomiting (n=2) (Figure 2)) within the 
first three months. All side-effects settled rapidly with cessation of opioids, and no hospitalisations 
were required. Additionally, three participants required increased opioid doses for pain, two 
participants died as a result of disease progression during follow-up, and three identified that 
clinical benefit had wained.  One participant had a single episode of urinary retention that did not 
necessitate study withdrawal but may have been caused or exacerbated by the anti-cholinergic 
effects of morphine.  
At three months after commencing phase IV, of the 24 people still taking opioids for breathlessness 
and keeping a diary, 12 were taking 10mg of sustained release morphine per 24 hours and 12 were 
taking 20mg. Nineteen were on the same dose from which they left the phase II dose-ranging study 
period, 4 had increased their dose by 10mg/24hours, and one had decreased their dose by 
10mg/24hours. Another 4 participants continued on their sustained release opioid but did not 
continue their diary.  
 
Patient-identified problems - breathlessness 
Using any of the first three ranked problems identified by participants on the Magill Quality of Life 
scale at baseline and on completion of the study or withdrawal, there was a significant decline in 
reports of breathlessness and significant increase in the number of people who were constipated.  
(Table 4) 
 
None of the following factors identified individuals more likely to benefit from opioids and to 
progress to the phase IV period of the study: gender, age (≤75 or greater), baseline MRC scores (4 
versus 2,3), baseline VAS severity (≤60 or greater), AKPS (40,50 versus ≥60), Magill Quality of 
Life at baseline (≤5 versus >5), BMI (≤25 versus > 25), nor primary diagnosis (cancer / non-
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cancer). Since potential univariate predictors were not significant, a multivariable model was not 
created. 
 
Toxicity 
No study participants presented to healthcare providers: none were hospitalised for respiratory 
depression, decreased level of consciousness or delirium. People who chose to cease their sustained 
release morphine because of lack of effect or side-effects did so without a withdrawal syndrome.  
   
Discussion  
Principal findings 
This study confirms that some people respond to opioid therapy when administered for refractory 
breathlessness, and that the benefit can be maintained over time. Despite concerns about treating 
infirm, elderly individuals with opioids, study participants did not encounter severe toxicity; while 
some side-effects did occur, these were a rare occurrence and resolvable. Because morphine is 
excreted by the kidneys changes in renal function should prompt re-evaluation of dosing in the 
chronic setting. Opioids provide net clinical benefits in this setting having accounted for unwanted 
side-effects, especially since all side-effects were quickly reversed with dose reduction or 
medication cessation. Given knowledge of the metabolism of opioids, changes in renal function on 
a stable dose of opioids would be one such concerning scenario. The net clinical benefit is in 
favour of the use of opioids in this setting especially considering that any side-effects were rapidly 
reversed with dose reduction or cessation.  
 
It needs to be emphasised that the way opioids have been used in this study is distinctly different to 
the way that they are used for acute pain in opioid naïve patients. Opioids were administered as 
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around-the-clock steady state dosing, more consistent with the management of chronic pain in 
opioid-tolerant patients. 
 
Is the reduction in breathlessness clinically significant? Beyond evaluating whether patients 
consider the net clinical benefit sufficient to continue a therapy, there are several ways that 
minimal clinically important differences have been approached in the literature: statistically using 
distribution estimates; expert consensus opinion, patient preference; and anchor approaches.[18]  A 
reduction in an observation by a level of greater than 50% of the standard deviation of the original 
observation is likely to be meaningful in measures such as quality of life.[19] In this study, the 
initial standard deviation of the observation was 19.2mm, so any reduction of greater than 9.6mm 
would exceed a 50% reduction in the standard deviation of the initial observation. The overall 
reduction in breathlessness for all 85 participants (responders and non-responders) at the end of the 
titration period was 11.7mm on the VAS, or a 61% reduction, suggesting that this is likely to be 
clinically significant.  
 
What other conclusions do these data support? 
These data are consistent with a mediating role of opioids in people with refractory dyspnoea 
without compromising respiratory function,[6,20] and are consistent with phase III studies that 
have been reported to date.[1,5] This current study supports the use of opioids for longer periods of 
time with no clinically significant respiratory compromise, and no evidence of tachyphylaxis. 
 
Do these findings differ from any other reported data? 
These data challenge widely held beliefs that opioids should not be used in people with respiratory 
compromise. Such beliefs are not based on data from people on regular low dose opioids, and, in 
fact, none of the study participants had an episode of respiratory compromise.  The data also 
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challenges concerns about the withdrawal of opioids when they are no longer effective or not 
wanted.   
 
Strengths of the study 
The study, spread across four sites with differing referral patterns, can be extrapolated to other 
clinical settings. The study followed people closely throughout the time that they were on opioids, 
without loss to follow-up. The primary outcome measure of intensity of breathlessness is the 
primary concern of people with ongoing refractory breathlessness.   
 
Limitations of the study – design 
The threshold of 10% for response was arbitrary.When other thresholds were considered in a 
sensitivity analysis, at 15% and 20% there are still a substantial number of people who derive 
benefit from opioids. The absence of end-tidal carbon dioxide measurement or oxygenation is 
unfortunate, but the absence of significant respiratory compromise is reassuring. However the 
study was designed during a time when easily portable, affordable, community-based assessment 
of end-tidal carbon dioxide was not available and it was felt that the burden of arterial blood gas 
measurements in this patient group was not supportable. Dose titration stopped at 30mg per 24 
hours given the levels of toxicity reported in a earlier study that used higher doses of opioids in the 
chronic setting.[21]  
 
These results may under-represent the net clinical benefit. As with pain, people may increase 
activity as the symptom is better controlled but report only marginal improvement in the symptom 
itself. As such, future work in this area needs to have a meticulous understanding of differential 
changes in functional status over each person’s own baseline. 
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Limitations of the study - sample 
People with heart failure are under-represented in the sample, and given encouraging evidence that 
they may be a diagnostic group who may respond well to opioids for their refractory dyspnoea, this 
is not ideal.[22,23] The sample deliberately did not engage people with acute exacerbations of 
breathlessness, although this would be an area for future research.  
 
Generalizability 
This study represents findings from several sites with people whose unifying feature is the severity 
of their breathlessness. Fundamentally, there is a question of whether underlying pathologies 
generate distinct types of breathlessness that are equally responsive to opioids. Whether the 
underlying aetiology of breathlessness is sufficiently uniform to allow interchangability of 
symptomatic therapies between differing pathologies is not finally determined. The predominant 
diagnosis was people with COPD, the area in which most work has been done in breathlessness to 
date.[6,24]  
 
Implications for clinicians and policymakers  
This study adds to the weight of evidence that opioids can be used judiciously in people with 
refractory breathlessness without compromising their health. Benefit was sustained in more than 
half of the people who gained an initial response without undue side-effects. The majority of the 
follow-up was done by general practitioners in the community and these should be the practitioners 
who manage dyspnoea using opioids in the future.    
  
Unanswered questions and future research 
These data support the need for a subsequent study exploring whether incremental dose increases 
in opioid responders would provide further symptom relief and hence a dose-response relationship. 
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Future work with opioids also needs to distinguish between changes in the intensity of 
breathlessness and the affect of unpleasantness that it engenders, and seek to compare the net 
clinical benefit of different opioids. Non-invasive measures of changes in the partial pressure of 
carbon dioxide and oxyhaemaglobin saturation in the first days of dose initiation or dose increment 
should be monitored.  
 
The study highlights a key challenge for many new therapies – it is not practicable to power 
adequately rigorous studies for an expected but extremely rare toxicity. Although respiratory 
depression is the key concern in prescribing opioids for breathlessness, powering a study for safety 
with a very rare event as the basis for the sample size calculation is very difficult. This study 
underscores the need for good, publically available, and routinely collected pharmacovigilance 
studies for all therapies, including opioids in breathlessness.[25]  
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Table 1 – Modified Medical Research Council (MRC) Dyspnea Scale13  
 
Grade 
 
Description of symptom 
0 “I only get breathless with strenuous exercise” 
1 “I get short of breath when hurrying on the level or walking up a slight hill” 
2 “I walk slower than people of the same age on the level because of 
breathlessness or have to stop for breath when walking at my own pace on 
the level” 
3 “I stop for breath after walking about 100 yards or after a few minutes on 
the level” 
4 “I am too breathless to leave the house” or “I am breathless when dressing” 
 
Note: This modified MRC scale uses the same descriptors as the original MRC scale in which 
the descriptors are numbered 1-5.  
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Table 2 – Characteristics of participants 
 
 n   % 
Gender Male 55 65 
Diagnosis Chronic obstructive pulmonary disease 50 59 
Lung cancer 19 22 
Interstitial lung disease 10 12 
Other causes 6 7 
 
 Mean Standard 
deviation 
Median Range 
Age 74 8.8  51-88 
Dyspnoea score (100mm visual analogue 
scale (VAS)) 
51.9 19.2 56.8 11.0-81.3 
Modified Medical Research Council Scale 
(mMRC)  
3.7 0.4 4.0 2-4 
Australian-modified Karnofsky 
Performance Status (0-100) 
63.1 60.0 9.49 40-80 
Body Mass Index (BMI) 24.9 24.9 9.1 14.2-38.4 
Magill Quality of life global rating (0-10) 5.9 6.0 2.1 0-10 
Participation in study (days) 139 189 25 2-665 
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Table 3 - Phase IV long term effectiveness study of people who have responded to once daily 
sustained release morphine for refractory dyspnoea (n=53).  
 Mean Standard 
deviation 
Median Range 
VAS as participants enter  phase IV study 34.5 17.1 38.0 1.8-70.5 
Improvement (mm on VAS entering phase 
IV study) from baseline 
17.5 11.7 13.5 2.2-61.6 
Individual percentage improvement over 
baseline entering phase IV study* 
35.4 21.1 30.3 10.1-85.74 
Dose of sustained release morphine (mg/24 
hours) entering phase IV (n=53) 
14.0 6.3 10.0 10 – 30 
Magill Quality of life global rating (0-10) 6.1 6.0 2.0 0-10 
*Equals baseline dyspnoea minus final dyspnoea divided by baseline dyspnoea 
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Table 4 – Participant ranked ‘physical symptoms or problems which have been the 
biggest problem for you over the past two (2) days’ at baseline and when last recorded from 
the Magill Quality of Life Questionnaire. 
 
 First 
ranked 
symptom 
concern 
p 
value** 
Symptom of 
concern 
ranked in the  
top three 
p value 
 
 
Breathlessness 
Baseline 
n = 85 
75  
 
<0.001 
80  
 
<0.001 Last 
recorded 
n = 81* 
40 56 
 
 
Constipation 
Baseline 
n = 85 
0  
 
<0.001 
 
8  
 
<0.001 Last 
recorded 
n = 81* 
14 27 
*Four participants died during the initial titration disease for reasons unrelated to the study 
medication, and one person withdrew before taking any medication. 
** McNemar’s Chi Squared test with continuity correction 
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